AstraZeneca Gets SEC Nod for New Trastuzumab Deruxtecan Indication in HER2-Positive Solid Tumors Parthika Patel10 Oct 2025 8:09 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended approval for an additional...
AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors Ruchika Sharma7 Oct 2025 2:51 PM ISTBangalore: AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import,...
AstraZeneca Pharma India gains CDSCO permission for Enhertu in HER2-positive solid tumours Ruchika Sharma4 Oct 2025 11:27 AM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate...
AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ Breast cancer treatment Ruchika Sharma24 Sept 2025 12:46 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) in combination...
AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication Ruchika Sharma9 May 2025 3:31 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate...
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer Ruchika Sharma3 March 2025 12:15 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer Ruchika Sharma28 Jan 2025 2:30 PM ISTAstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with...
USFDA grants priority review to AstraZeneca-Daiichi Sankyo Enhertu for HER2-low, HER2 Ultralow Breast Cancer Ruchika Sharma3 Oct 2024 9:15 AM ISTAstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and...
GST rates slashed for certain cancer drugs Yakshi Chugh10 Sept 2024 5:20 PM ISTNew Delhi: In an effort to reduce the overall cost for the treatment of cancer, the GST Council decided to reduce the GST rate on certain cancer drugs...
Health Bulletin 10/ September/ 2024 Yakshi Chugh10 Sept 2024 5:17 PM ISTHere are the Top health stories for the day: MCC NEET PG counselling 2024 tentative schedule out, registrations from Sept 20New Delhi- The...
GST rates reduced from 12 percent to 5 per cent on certain cancer drugs Ruchika Sharma10 Sept 2024 2:36 PM ISTNew Delhi: In an effort to reduce the overall cost for the treatment of cancer, the GST Council decided to reduce the GST rate on certain cancer...
AstraZeneca-Daiichi Sankyo Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Ruchika Sharma15 Aug 2024 10:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for...
